The selective cannabinoid receptor type 2 agonist lenabasum exhibited an acceptable safety profile while improving outcomes in patients with diffuse cutaneous systemic sclerosis, according to results of a phase II study.
Analysis of pooled data from three phase III trials (SPIRIT-P1, -P2 and -P3) reveals that ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, is a safe treatment for patients with active psoriatic arthritis (PsA), according to a study presented at the Annual European Congress of Rheumatology by the European League Against Rheumatism (EULAR 2018).
Diacerein appears to be more effective than glucosamine plus chondroitin for patients with mild-to-moderate knee osteoarthritis , according to a study presented at the 2018 Annual European Congress of Rheumatology (EULAR 2018).
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.
The selective T cell costimulation modulator abatacept drives a rapid improvement in proteinuria, which leads to earlier, sustained complete response compared with placebo in patients with active class III or IV lupus nephritis, although the rate of complete response is similar between groups, suggests a study presented at the EULAR 2018 Congress.
Patients with ankylosing spondylitis (AS) are nearly twice as likely to harm themselves compared with the general population, a Canadian study has shown, highlighting the need for tailored preventive strategies in these patients.